SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion centers on Trumps Iran conflict and fuel-price pressures, with critics linking the war and broader economic strain to political risk while supporters defend the administrations approach. Traders also debate DJTs weak, range-bound trading and speculate about how midterm prospects could affect sentiment.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

QNTs sharp, volatile rally and repeated tests of resistance are driving attention, with traders split between expecting another breakout and warning of profit-taking or further pullbacks. Bullish holders point to Quants institutional-payment work and potential token utility or staking as longer-term drivers, though the effect on QNT demand remains uncertain.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is drawing attention after Kodiaks wet AMD drug results heightened competitive concerns and coincided with a sharp OCUL selloff. Traders disagree on whether the move is an overreaction, with bulls pointing to AXPAXLIs potential durability and planned NDA filing while skeptics question its edge and commercial prospects against rival treatments.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is drawing attention for its prolonged, volatile pullback, with traders focused on weak price action and repeated resistance to a recovery. The debate centers on executive share sales and uncertainty around AI-data licensing and competition; bulls point to Reddits growth and data value, while bears question whether those opportunities can support the stock.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRXs sharp, high-volume breakout without a clear new announcement is driving attention, with traders attributing the move to possible institutional buying and short covering. The community is broadly bullish, though speculation about leaked FDA or commercial news remains unconfirmed; upcoming Anktiva label-expansion decisions and sales growth are cited as potential catalysts.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Novartis/Aviditys failed Phase 3 DM1 study has fueled concern that Sareptas own DM1 program may face similar efficacy hurdles, though bulls argue its delivery approach differs and say its data will be decisive. The broader discussion centers on waiting for DM1 and FSHD readouts amid continued frustration with SRPTs weak, volatile trading.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is drawing attention amid sharp natural-gas swings around EIA storage reports and changing weather forecasts, with some traders citing tighter storage and heat-driven demand as support for a rebound. Others remain bearish on shoulder-season demand, strong production and the funds futures-roll and leverage decay, making the move a contentious short-term trade.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

A weaker-than-expected September jobs report and downward revisions to prior payrolls eased traders expectations for another near-term Fed rate hike, helping lift the Dow and broader indexes. Bulls welcomed the rate-relief rally, while skeptics remained concerned about high Treasury yields, energy costs and fragile market breadth.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSM is drawing attention for its push toward recent highs, with traders pointing to bullish call activity and persistent AI-chip demand. A reported evaluation of a Texas fab campus alongside its Arizona expansion is adding to optimism about capacity growth, though some traders remain cautious about pullbacks and elevated expectations.

Corteva, Inc. is a global pure-play agriculture company that combines innovative technologies, high-touch customer engagement and operational execution to profitably deliver solutions for the world's most pressing agriculture challenges. It generates advantaged market preference through its unique distribution strategy, together with its balanced and globally diverse mix of seed, crop protection, and digital products and services. The company leverages recognized agricultural brands and a robust technology pipeline to maximize productivity for farmers while working with stakeholders throughout the food system to fulfill its promise of enriching the lives of those who produce and those who consume, ensuring progress for generations to come. Corteva was founded in 1802 and is headquartered in Indianapolis, IN.

Corteva Inc

Cortevas completed spin-off of its seed and genetics business into Vylor has driven intense volatility as CTVA is repriced as a standalone crop-protection company; many traders say the sharp apparent decline largely reflects the separation, while others see further selling and debate whether the remaining business is undervalued. Index-related selling is also cited as a possible source of pressure, but the community is divided on the post-spin valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aurinias Teva patent settlement, which delays generic voclosporin entry and recognizes key patent protections, is the main focus, alongside ongoing litigation with other generic challengers. Many traders see the settlement as reducing risk and improving the companys prospects, while others remain frustrated by the unresolved cases, limited company communication, and share-price stagnation.

Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company Stock

Revealing a significant insider sell on August 26, Stephen P Robertson, Chief Legal Officer at Aurinia Pharmaceuticals (NASDAQ:AUPH), as per the latest SEC filing.
What Happened: A Form 4 filing with the U.S. Securitiesread more...

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Aurinia Pharmaceuticals shares rise after settling patent litigation with Teva, which can launch generic voclosporin no earlier than December 2036.read more...

AUPH Stock Rallies 6% After-Hours  — Here’s Why 

Equity

Aurinia said it and its U.S. subsidiary reached an agreement with Teva Pharmaceuticals resolving patent infringement litigation tied to Teva’s application to sell a generic version of LUPKYNIS.  


Aurinia Settles Patent Litigation with Teva

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, Aurinia) have entered into a settlement agreement with Teva Pharmaceuticals Inc. (Teva) to resolve patent infringement litigation relating to Tevas filing of an...

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of +47.37% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and six months ended June 30, 2026 and provided an update on recent business progress. Financial Results Total Revenue: For the three and six months ended June 30, 2026, total revenue was $83.2 million and...

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates

NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of -8.33% and -45.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?

Karyopharm Therapeutics (KPTI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis (ClinicalTrials.gov). Planned enrollment is approximately 150...

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Neutral Sentiment

Up more than 5%

Flat to up 5%

Flat to down 5%

Down more than 5%

What&#39;s your expected total return for the S&amp;P 500 ($SPY) in Q4? 

Drop your reasoning in the comments.

Stocktwits

What's your expected total return for the S&P 500 (

) in Q4? 

Drop your reasoning in the comments.

Current Price	$15.83
Prev Close	$15.95
Open	$16.06
Dividend Yield	0.00%
50-Day Moving Average	$15.99
Beta	0.78
Avg. Volume	819,438.92
PE Ratio	6.92

52-Week High	$19.25
52-Week Low	$10.90
Market Capitalization	$2.12B
EPS (Annual)	$2.07
Price to Book	3.42
Revenue Per Employee	$2.21M

Feed

News

Sentiment

Earnings

Fundamentals

Info

AUPH Fundamentals